[1] |
张岚.淀粉样变性肾病诊断的病理技术探析[J].中外医学研究,2014,12(3):72-73.
|
[3] |
芦建华,卓莉,邹古明,等.47例肾淀粉样变性病的肾脏临床病理特点[J].中日友好医院学报,2014,28(2):81-84.
|
[4] |
董骏武,位红兰.骨髓瘤相关性肾淀粉样变性1例并文献复习[J].临床与实验病理学杂志,2014,30(3):332-334.
|
[5] |
王素霞,邹万忠,王梅,等.肾脏早期淀粉样变临床病理特点[J].中华病理学杂志,2013,32(2):120-123.
|
[2] |
Chew DP,Aroney CN,Aylward PE,et al.Definition of organ involvement and treatment response in primary systemic amyloidosis(AL):a consensus opinion from the 10thInternational Symposium on Amyloid and Amyloidosis,Tours,France,18-22 April 2004[J].Am J Hematol,2015,90(4):319-328.
|
[6] |
隋燕霞,蒋娜,解立怡,等.淀粉样变性肾病31例临床病理学分析[J].临床与实验病理学杂志,2014,30(20):1379-1382.
|
[7] |
杨永刚.老年及老年前期肾淀粉样变性和皮肤淀粉样变性临床研究[J].中国继续医学教育,2015,7(12):78-79.
|
[8] |
陈汝,詹锋,符克英.4例肾淀粉样变的病理分析[J].中国热带医学,2008,8(6):970-971.
|
[9] |
Migrino RQ,Harmann L,Christenson R,et al.Clinical and imaging predictors of 1-year and long-term mortality in light chain(AL)amyloidosis:a 5-year follow-up study[J]. Heart Vessels,2013,29(6):793-800.
|
[10] |
曹建南,黄海望,王玉新.46例成人肾病综合征临床与病理分析[J].福建医药杂志,2007,29(2):10-12.
|
[11] |
Kastritis E,Roussou M,Gavriatopoulou M,et al.Long-term outcomes of primary systemic light chain(AL)amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies[J].Am J Hematol,2015,90(12):E60-E65.
|
[12] |
柳红婷,郭鹏,张亚莉.肾病综合征104例临床病理分析[J].基层医学论坛,2015,19(z1):67-68.
|
[13] |
张喜卿,张同全,孙明祥,等.肾淀粉样变性临床病理学分析[J].实用医药杂志,2016,23(3):272-274.
|
[14] |
Audard V,Matignon M,Weiss L,et al.Successful longterm outcome of the first combined heart and kidney transplant in a patient with systemic AL amyloidosis[J].Am J Transplant,2015,9(1):236-240.
|
[15] |
彭丽,王艳.糖尿病肾病合并非糖尿病肾病患者的病理分析[J].中外医学研究,2013,11(35):7-9.
|
[16] |
陈浩,曾彩虹,刘志红.膜性肾病合并系统性淀粉样变性[J].肾脏病与透析肾移植杂志,2012,21(6):577-581.
|
[17] |
张育安.肾淀粉样变性病的肾脏病理损伤研究进展[J].国际泌尿系统杂志,2013,33(2):264-270.
|